NASDAQ: PYPDPolypid Ltd Stock
$4.30-0.14 (-3.15%)
Updated Apr 18, 2024
PYPD Price
$4.30
Fair Value Price
-$4.39
Market Cap
$7.11M
52 Week Low
$3.57
52 Week High
$13.50
P/E
0.25x
P/B
-3.39x
P/S
N/A
PEG
0.01x
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$23.87M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-8.33
Operating Cash Flow
-$17M
Beta
0.79
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PYPD Overview
PolyPid LTD. is developing products based on a polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs and improve surgical results. The company's lead product candidate is D-PLEX100, to prevent sternal (bone) and abdominal (soft tissue) surgical site infections. PolyPid was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PYPD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PYPD ($4.30) is overvalued by 197.87% relative to our estimate of its Fair Value price of -$4.39 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PYPD ($4.30) is not significantly undervalued (197.87%) relative to our estimate of its Fair Value price of -$4.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PYPD ($4.30) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PYPD due diligence checks available for Premium users.
Be the first to know about important PYPD news, forecast changes, insider trades & much more!
PYPD News
Valuation
PYPD fair value
Fair Value of PYPD stock based on Discounted Cash Flow (DCF)
Price
$4.30
Fair Value
-$4.39
Undervalued by
197.87%
PYPD ($4.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PYPD ($4.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PYPD ($4.30) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PYPD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.25x
Industry
15.68x
Market
41.33x
PYPD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PYPD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PYPD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.39x
Industry
5.76x
PYPD price to earnings growth (PEG)
For valuing profitable companies with growth potential
PYPD is good value based... subscribe to Premium to read more.
PEG Value Valuation
PYPD's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.4M
Profit Margin
0%
PYPD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$15.4M
Liabilities
$17.5M
Debt to equity
-8.33
PYPD's short-term liabilities ($7.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PYPD's long-term liabilities ($10.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PYPD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PYPD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PYPD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PYPD vs Biotech Stocks
Polypid Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.